Myoclonic Epilepsy Overview

Save information for later
Sign Up

Learn About Myoclonic Epilepsy

What is the definition of Myoclonic Epilepsy?
Myoclonic epilepsy is a type of seizure disorder characterized by quick jerking movements due to uncontrolled muscle contractions caused by abnormal electrical impulses in the brain. Unlike grand mal (tonic-clonic) seizures, during a myoclonic seizure the affected individual does not lose consciousness. There are several types of myoclonic epilepsy, including infantile spasms, Lennox-Gastaut Syndrome, juvenile myoclonic epilepsy, and progressive myoclonic epilepsy, among others.
What are the symptoms of Myoclonic Epilepsy?
Symptoms of myoclonic epilepsy depend on the type and usually affects the neck, shoulders, and upper arms. Symptoms of myoclonic epilepsy may include quick, uncontrolled muscle jerks; rhythmic movements; arms flinging outward; knees pulling up; body stiffening; and unusual clumsiness. Myoclonic seizures may occur with atonic seizures, which cause limp muscles. When myoclonic epilepsy worsens, it is known as progressive myoclonic epilepsy, which is a rare seizure disorder characterized by both myoclonic and tonic-clonic (grand mal) seizures.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Myoclonic Epilepsy?
Treatment for myoclonic epilepsy depends on the type, frequency, and severity of the seizures and may include anti-seizure (anti-epileptic) medications, ketogenic diet, vagus nerve stimulator (VNS) implantation, and surgery.
Who are the top Myoclonic Epilepsy Local Doctors?
Dr. Thomas A. Craig
Geriatrics | Internal Medicine
Dr. Thomas A. Craig
Geriatrics | Internal Medicine

Stormont Vail Health Flint Hills LLC

1110 Saint Marys Rd, 
Junction City, KS 
 (1.4 mi)
785-762-2585
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Thomas Craig is a Geriatrics specialist and an Internal Medicine provider in Junction City, Kansas. Dr. Craig and is rated as an Experienced provider by MediFind in the treatment of Myoclonic Epilepsy. His top areas of expertise are Hypertension, Familial Hypertension, Glucocorticoid-Remediable Aldosteronism, Hip Replacement, and Gastrostomy. Dr. Craig is currently accepting new patients.

Dr. Nanda N. Kumar
Neurology
Dr. Nanda N. Kumar
Neurology
222 N 6th St, 
Manhattan, KS 
 (17.8 mi)
785-537-9349
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Nanda Kumar is a Neurologist in Manhattan, Kansas. Dr. Kumar and is rated as an Advanced provider by MediFind in the treatment of Myoclonic Epilepsy. His top areas of expertise are Essential Tremor, Chronic Inflammatory Demyelinating Polyneuropathy, Seizures, and Parkinson's Disease. Dr. Kumar is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Dr. Casey M. Poell
Pediatrics | Internal Medicine
Dr. Casey M. Poell
Pediatrics | Internal Medicine

Ascension Via Christi Hospital Manhattan Inc

1823 College Ave, 
Manhattan, KS 
 (17.2 mi)
785-776-3322
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Casey Poell is a Pediatrics specialist and an Internal Medicine provider in Manhattan, Kansas. Dr. Poell and is rated as an Experienced provider by MediFind in the treatment of Myoclonic Epilepsy. His top areas of expertise are Necrosis, Sepsis, Pneumonia, Hip Replacement, and Endoscopy. Dr. Poell is currently accepting new patients.

View All Doctors
What are the latest Myoclonic Epilepsy Clinical Trials?
Open-Label, Single-Arm, Phase 3 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
Open-Label, Single-Arm, Phase 3 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
Enrollment Status: Recruiting
Publish Date: February 12, 2025
Intervention Type: Drug
Study Phase: Phase 3

Summary: The primary purpose of this study is evaluate the safety and tolerability of fenfluramine hydrochloride (HCl) 0.2 to 0.8 mg/kg/day in infants 1 year to less than 2 years of age with Dravet syndrome.

Match to trials
Find the right clinical trials for you in under a minute
Get started
CureDRPLA Global Patient Registry for Individuals With Dentatorubral-pallidoluysian Atrophy (DRPLA)
CureDRPLA Global Patient Registry for Individuals With Dentatorubral-pallidoluysian Atrophy (DRPLA)
Enrollment Status: Recruiting
Publish Date: February 11, 2025

Summary: The objective of the CureDRPLA Global Patient Registry is to establish a longitudinal database of patient-reported data on individuals affected with Dentatorubral-pallidoluysian atrophy (DRPLA) from anywhere in the world. The CureDRPLA Global Patient Registry will address patient needs by: * Expanding patient engagement by documenting quality of life outcomes. * Providing anonymized data to the DR...

View All Clinical Trials